Ingredients like yohimbine carry real safety risks
The peptides under review at the July 2026 FDA meeting including BPC-157, TB-500, CJC-1295, and others are not FDA-approved drugs and will not become FDA-approved drugs as a result of this meeting
Peptide origin / Partial sequence of human gastric protein BPC, isolated from gastric juice Molecular weight / Approximately 1,419 Da (15 amino acids) Common off-label oral dose / 250 to 500 mcg twice daily, taken on an empty stomach Common off-label subcutaneous dose / 200 to 300 mcg once or twice daily near the affected area or abdominally Evidence level / Preclinical only (GRADE: very low certainty for human GI healing) Key preclinical finding / Accelerated gastric ulcer healing in rats within 24 to 72 hours across multiple models Route preference for GI targets / Oral administration, based on topical mucosal contact rationale Safety profile in humans / Largely unknown
"Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures
This supports the discussion of GSH as a major cellular redox buffer, antioxidant, and enzyme cofactor
Jill James, Paul Cutler, Stepan Melnyk, Stefanie Jernigan, Laurette Janak, David W Gaylor, and James A Neubrander
